Stemtech Corp
Close on Oct 19, 2026
- Market cap
- $207.74K
- P/E (TTM)
- –
- Dividend yield
- –
About Stemtech
Wholesale-Drugs, Proprietaries & Druggists' Sundries, SIC 5122
Stemtech Corporation is a network marketing company that develops and markets dietary supplements and skincare products designed to support adult stem cell physiology and wellness. Its supplement offerings, such as the RCM System, stemrelease3, StemFlo, MigraStem, and pet supplements, utilize plant-based botanicals formulated to assist the release, circulation, and tissue migration of adult stem cells. The company also produces oral healthcare items, including OraStem toothpaste, alongside topical skincare treatments like Cellect One Rapid Renew Night Cream and Cellect One Shield mist. Products reach consumers globally through independent business partners and direct-to-consumer distribution channels.
The company operates internationally across geographic segments in the Americas, Latin America, and Asia. Stemtech conducts business through thirteen subsidiaries located in jurisdictions including the United States, Canada, Mexico, Malaysia, Taiwan, and Ecuador. Principal executive offices and corporate headquarters are located in Naples, Florida.
Summary of the business section of Stemtech's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Stemtech Corp
- Founded
- 2009
- Headquarters
- Naples, FL
- Address
- 4851 Tamiami Trail North, Suite 200 34103
- Phone
- (954) 715-6000
- Website
- stemtech.com
- Industry
- Wholesale-Drugs, Proprietaries & Druggists' Sundries
- Fiscal year ends
- December 31
- Auditor
- Bush & Associates CPA LLC, Las Vegas, Nevada
Stock & identifiers
- Ticker
- STEK
- Exchange
- OTC
- Shares outstanding
- 3.00B, Aug 13, 2026
- Public float
- $5.65M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
- SEC CIK
- 1511820
- EIN
- 87-2151440
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Benjamin Nathaniel Kaplan | Director | 2,134,094 |
Corporate history
Events identified from SEC filings